Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | ACR | P10323 | 5/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7309964 | 0.96 | ACR (0.42) | KMT2AMEN1ACRPRSS1MAPT | |
| SCHEMBL1399026 | 0.86 | KMT2A (0.43) | KMT2AMEN1ACRPRSS1MAPT | |
| SCHEMBL1996805 | 0.83 | PRSS1 (0.60) | KMT2AMEN1ACRPRSS1MAPT | |
| SCHEMBL4597132 | 0.83 | MAPT (0.41) | KMT2AMEN1ACRPRSS1MAPT | |
| SCHEMBL1399025 | 0.82 | ACR (0.41) | KMT2AMEN1ACRPRSS1MAPT | |
| SCHEMBL11313701 | 0.82 | KMT2A (0.54) | KMT2AMEN1ACRPRSS1SMN1; SMN2 | |
| SCHEMBL10956570 | 0.80 | KMT2A (0.56) | KMT2AMEN1ACRPRSS1MAPT | |
| SCHEMBL2917664 | 0.79 | ACR (0.40) | KMT2AMEN1ACRPRSS1MAPT | |
| SCHEMBL11302255 | 0.79 | LMNA (0.52) | KMT2AMEN1ACRPRSS1MAPT | |
| SCHEMBL7328271 | 0.78 | ACR (0.58) | KMT2AMEN1ACRPRSS1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208882-A1 | Organic Compounds | DANAHAY HENRY LUKE (GB) | 2012-08-16 | — | — | US | disclosed |
| EP-2305639-A2 | Organic compounds | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| EP-2253612-A1 | Organic compounds | Novartis AG (CH) | 2010-11-24 | — | — | EP | disclosed |
| US-20090203777-A1 | ORGANIC COMPOUNDS | MAAS, JANET CATHERINE (GB) | 2009-08-13 | — | — | US | disclosed |
| EP-1874726-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006108643-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208882-A1 | Organic Compounds | CFTR, OTC, ASIC1 | KMT2A 3928/4885MEN1 4069/4885ACR 2022/4885 |
| US-20090203777-A1 | ORGANIC COMPOUNDS | CFTR, OTC, ASIC1 | KMT2A 3928/4885MEN1 4069/4885ACR 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.